Abstract
Pancreatic cancer has a poor response to conventional chemotherapy and radiotherapy. Inhibition of matrix metalloproteinase activity involved in tumour invasion and metastases is a novel biological approach for cancer treatment. This multicentre phase II clinical trial assessed marimastat, an oral matrix metalloproteinase inhibitor, in patients with advanced pancreatic cancer. A total of 113 patients received marimastat for 28 days at 100 mg b.d. (n = 9), 25 mg o.d. (n = 90) or 10 mg b.d. (n = 14). Patients with a response to treatment could continue marimastat beyond 28 days. Of 113 patients, 90 (80%) completed the 28-day study and 83 (73%) continued treatment. The principal side effect was arthralgia in 14 (12%) patients at 28 days and 33 (29%) patients over the whole study. There were 31 patients (27%) who required dose modification. Of 76 patients with evaluable CA19-9 levels, 23 (30%) showed no increase or fall in CA19-9. Of 83 patients with radiologically assessable disease, 41 (49%) had stable disease. The median survival was 245 days for those with a stable or falling CA19-9 level 128 days in those with rising CA19-9. The overall survival was 3.8 months. 5.9 months for stage II, 4.7 months for stage III and 3 months for stage IV disease. Of 90 patients, 46 (51%) had stabilization or reduction in pain, mobility and analgesia scores. Further development and clinical evaluation of matrix metalloproteinase inhibitors for the treatment of pancreatic cancer is warranted. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Bakkevold KE (1998) Chemotherapy for unresectable pancreatic cancer. In: Beger H, Warshaw AL, Buchler MW, Carr-Locke DL, Neoptolemos JP, Russell C, Sarr MG (eds). The Pancreas, pp. 1120–1138, Blackwell Science: Oxford
Beckett RP, Davison AH, Drummond AH, Huxley P and Whittaker M (1996) Recent advances in matrix metalloproteinase inhibitor research. Drug Dev Today 1: 16–26
Bramhall SR, Lemoine N, Stamp G, Donovan IA, Dunn J and Neoptolemos JP (1994) 72kDa collagenase, Stromelysin 1 and tissue inhibitor of metalloproteinase 1 expression in pancreatic cancer. Digestion 55: 286
Bramhall SR, Allum WH, Cummings C, Jones AG, Attwood A and Neoptolemos JP (1995) Incidence, treatment and outcome in 13,600 cases of pancreatic cancer: An epidemiological study in the West Midlands. Br J Surg 82: 111–115
Bramhall SR, Stamp G, Dunn J, Lemoine N and Neoptolemos JP (1996) Expression of collagenase (MMP2), stromelysin (MMP3) and tissue inhibitor of metalloproteinases (TIMP1) in pancreatic and ampullary disease. Br J Cancer 73: 972–978
Bramhall SR, Lemoine N, Stamp G and Neoptolemos JP (1997) Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic cancer. J Pathol 182: 347–355
Bramhall SR, Rosemurgy A, Brown PD, Bowry C and Buckels JA (2001) Marimastat as first line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 19: 3447–3455
Brenner DA, Ohara M, Angel P, Chojkier M and Karin M (1989) Prolonged activation of jun and collagenase genes by tumour necrosis factor alpha. Nature 337: 661–663
Brown PD, Bloxidge RE, Stuart NSE, Gatter KC and Carmichael J (1993) Association between expression of activated 72-kilodalton gelatinase and tumour spread in non-small cell lung carcinoma. J Natl Cancer Inst 85: 574–578
Burris HA, Moore MJ, Andersen J, Green M, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Torniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD and Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: a randomized trial. J Clin Oncol 15: 2403–2413
Campo E, Merino MJ, Tavassoli FA, Charonis AS, Stetler-Stevenson WG and Liotta LA (1992) Evaluation of basement membrane components and the 72kDa type IV collagenase in serous tumours of the ovary. Am J Surg Pathol 16: 500–507
Cancer of the Pancreas Task Force (1981) Staging cancer of the pancreas. Cancer 47: 1631–1642
Delaisse JM and Vaes G (1992) Mechanism of mineral solublisation and matrix degradation in osteoclastic bone resorption. In: Rifkin BR and Gay CV (eds). Biology and Physiology of the Osteoclast, pp. 290–314, CRC Press: Boca Raton, Florida
Drummond A, Beckett P and Bone et al (1995) BB-2516: an orally bioavailable matrix metalloproteinase inhibitor with efficacy in animal cancer models. Proc Am Assoc Cancer Res 36: 100 (Abstract)
Frey C, Twomey P, Keehn R, Elliot D and Higgins G (1980) Randomized study of 5-FU and CCNU in pancreatic cancer: Report of the veterans administration surgical adjuvant cancer chemotherapy study group. Cancer, 27–31
Glimelius B, Hoffman K, Sjoden P-O, Jacobsson G, Sellstrom H, Enander L-K, Linne T and Svensson C (1996) Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 7: 593–600
Greene J, Wang M, Liu YE, Raymond LA, Rosen C and Shi YE (1996) Molecular cloning and characterisation of human tissue inhibitor of metalloproteinase 4. J Biol Chem 271: 30375–30380
Gress TM, Muller-Pillasch F, Lerch MM, Freiss H, Buchler M and Alder G (1995) Expression and in-situ localisation of gene coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer. Int J cancer 62: 407–413
Harris E (1990) Rhematoid arthritis: pathophysiology and implications for therapy. N Engl J Med 322: 1277–1289
Jones L, Ghaneh P, Humphreys M and Neoptolemos JP (1999) The matrix metalloproteinases and their inhibitors in the treatment of pancreatic cancer. Ann N Y Acad Sci 880: 288–307
Jones LE, Campbell F and Neoptolemos JP (2000) The expression of matrix metalloprotinases (MMPs 1, 2, 3, 7, 8, 9, 12 and 14) and their inhibitors (TIMP 1, 2 and 3) in pancreatic adenocarcinoma. Br J Surg 87: 676
Liotta LA and Stetler-Stevenson WG (1991) Tumour invasion and metastasis: An imbalance of positive and negative regulation. Cancer Res 51 (Suppl): 5054–5059
Mallinson CN, Rake MD, Cocking JB, Fox CA, Cwynarski MT, Diffey BL, Jackson GA, Hanley J and Wass VJ (1980) Chemotherapy in pancreatic cancer: results of a controlled prospective randomized multicentre trial. Br Med J 281: 1589–1591
Mori M, Barnard GF, Mimori K, Ueo H, Akiyoshi T and Sugimachi K (1995) Overexpression of matrix metalloproteinase 7 mRNA in human colon carcinomas. Cancer 7 (5)(Suppl):1516–1519
Nomura H, Sato H, Seiki M, Mai M and Okada Y (1995) Expression of membrane-type matrix metalloproteinase in human gastric carcinomas. Cancer Res 55: 3263–3266
Northern and Yorkshire Cancer Registry Information Service (2000) Cancer treatment policies and their effects on survival: Pancreas. NYCRIS: Leeds, UK(In press)
Pajouh MS, Nagle RB, Breatynach R, Finch JS, Brawler MK and Bowden GT (1991) Expression of metalloproteinase genes in human prostate cancer. J Cancer Res Clin Oncol 117: 144–150
Palmer KR, Kerr M, Knowles G, Cull A, Carter DC and Leonard RCF (1994) Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg 81: 882–885
Porte H, Chastre E, Prevot S, Nordlinger B, Empereur S, Basset P, Chambon P and Gespach C (1995) Neoplastic progression of human colorectal cancer is associated with overexpression of the stromelysin 3 and NM-40/SPARC genes. Int J Cancer 64: 70–75
Sellers A, Murphy G, Meickle MC and Reynolds JJ (1997) Rabbit bone collagenase inhibitor blocks the activity of other neutral metalloproteinases. Biochem Biophys Res Commun 87: 581–587
Smith PF, Hoth DF, Levin B, Karlin DA, MacDonald JS and Wooley PV (1980) 5-Fluorouracil, adriamycin and mitimycin C (FAM) chemotherapy for advanced adenocarcinoma of the pancreas. Cancer 46: 2014–2018
Stetler-Stevenson WG (1989) Tissue inhibitor of metalloproteinase (TIMP 2). J Biol Chem 264: 17374–17378
Uria JA, Ferrando AA, Velasco G, Freije JMP and Lopez-Otin C (1994) Structure and expression in breast tumours of human TIMP 3, a new member of the metalloproteinase inhibitor family. Cancer Res 54: 2091–2094
Wolf C, Chenard MP, Durand de Grossouvre P, Bellocq JP, Chambon P and Basset P (1992) Breast-cancer-associated stromelysin-3 gene is expressed in basal cell carcinoma and during cutaneous wound healing. J Invest Dermatol 99: 870–872
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Evans, J., Stark, A., Johnson, C. et al. A phase II trial of marimastat in advanced pancreatic cancer. Br J Cancer 85, 1865–1870 (2001). https://doi.org/10.1054/bjoc.2001.2168
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.2168
Keywords
This article is cited by
-
Repurposed drugs and their combinations prevent morbidity-inducing dermonecrosis caused by diverse cytotoxic snake venoms
Nature Communications (2023)
-
The matrix metalloproteinase inhibitor marimastat inhibits seizures in a model of kainic acid-induced status epilepticus
Scientific Reports (2020)
-
The exploration of network motifs as potential drug targets from post-translational regulatory networks
Scientific Reports (2016)
-
Neutrophil granulocyte derived MMP-9 is a VEGF independent functional component of the angiogenic switch in pancreatic ductal adenocarcinoma
Angiogenesis (2011)
-
MMP-2 siRNA induced Fas/CD95-mediated extrinsic II apoptotic pathway in the A549 lung adenocarcinoma cell line
Oncogene (2007)